Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

Gland Pharma appoints Dr Reddy’s senior executive Deepak Sapra as CEO

Дата публикации: 14-08-2026 03:36:14

Gland Pharma has appointed Deepak Sapra as its new chief executive officer, with his tenure set to begin on November 16, 2026, subject to his acceptance of the offer. Sapra brings 27 years of executive experience, including over 23 years in pharmaceuticals, and currently leads API and Services at Dr Reddy’s Laboratories.

Основное содержимое страницы с новостью.

Gland Pharma appoints Dr Reddy’s senior executive Deepak Sapra as CEO

ET OnlineLast Updated: Aug 14, 2026, 09:06:00 AM IST

Synopsis

Gland Pharma has appointed Deepak Sapra as its new chief executive officer, with his tenure set to begin on November 16, 2026, subject to his acceptance of the offer. Sapra brings 27 years of executive experience, including over 23 years in pharmaceuticals, and currently leads API and Services at Dr Reddy’s Laboratories.

Gland PharmaAgencies

Gland Pharma has appointed Dr Reddy’s Laboratories’ Deepak Sapra as CEO, effective November 16, 2026, subject to his acceptance of the offer. (File photo)

Gland Pharma has appointed Deepak Sapra as its new chief executive officer, with the pharma company saying he will assume charge from November 16, 2026, subject to his acceptance of the offer.

The appointment was approved by the company's board based on the recommendation of its Nomination and Remuneration Committee, Gland Pharma said in a regulatory filing on Friday.

Sapra has 27 years of executive experience, including more than 23 years in the pharmaceutical industry. He currently serves as CEO – API and Services at Dr Reddy's Laboratories and is a board member of Aurigene Pharma Services.


At Dr Reddy's, Sapra is responsible for global portfolio strategy and leads an integrated B2B business covering generic pharmaceuticals, CDMO services, APIs, collaborations and alliances, public health and global patient access.

He has experience across business development, licensing, mergers and acquisitions, portfolio creation and market expansion across India and major international markets, including the US, Europe, Japan, Latin America, Africa and Asia-Pacific. His experience spans areas including CDMO partnerships, generics, APIs, sales and marketing, supply chain, R&D and operations.

Before his current role, Sapra served as CEO – Custom Pharmaceutical Services, where he led a global CDMO business serving innovator pharmaceutical companies in the US, Europe and Japan. Between 2011 and 2015, he held senior leadership roles in global generics business development and portfolio management.

Sapra holds a bachelor's degree in mechanical engineering from the Indian Railways Institute of Mechanical and Electrical Engineering, Jamalpur, and a master's degree in management from IIM Bangalore. He has also been a Chevening Scholar at the University of Bradford and a Fulbright Fellow at Carnegie Mellon University.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Глава SAP в России покинула свой пост0011-10-2018
2Nox Health Appoints New CEO0529-06-2026
3Apnimed Appoints New CEO as Investigational OSA Therapy Nears FDA Decision0522-06-2026
4STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive05.127-07-2026
5Dr. Reddy’s to delay semaglutide supplies due to quality issue, shares hit-2609-07-2026
6Vikaas M Sachdeva to lead BitDelta India as Chief Executive Officer 09.3707-04-2026
7A Change at the Top at Water-Heater Maker A.O. Smith0523-06-2026
8Daikin Applied Announces New Top Leadership0502-07-2026
9Экс-глава Удмуртии Бречалов стал гендиректором компании «Апекс»024.2911-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 10.64. Источник: economictimes.indiatimes.com.